Literature DB >> 7509279

Dissociation of TNF-alpha cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-alpha mutants.

J A Barbara1, W B Smith, J R Gamble, X Van Ostade, P Vandenabeele, J Tavernier, W Fiers, M A Vadas, A F Lopez.   

Abstract

Human tumour necrosis factor alpha (TNF-alpha) is a pleiotropic cytokine capable of killing mammalian tumour cells in vitro and in vivo, and of enhancing the proinflammatory activity of leucocytes and endothelium, the latter effects limiting its usage as an antitumour agent in humans. Using TNF-alpha mutants with a selective capacity to bind to the TNF p55 receptor (TNFR55) or to the p75 receptor (TNFR75) we show here that these two major activities of TNF-alpha can be dissociated. The TNFR55-selective mutants (R32W, E146K and R32W-S86T) which bind poorly to TNFR75 displayed similar potency to wild-type TNF in causing cytotoxicity of a human laryngeal carcinoma-derived cell line (HEp-2) and cytostasis in a human leukaemic cell line (U937). However, these TNFR55-selective mutants exhibited lower proinflammatory activity than wild-type TNF. Specifically, TNF-alpha's priming of human neutrophils for superoxide production and antibody-dependent cell-mediated cytotoxicity, platelet-activating factor synthesis and adhesion to endothelium were reduced by up to 170-fold. Activation of human endothelial cell functions represented by human umbilical venular endothelial cell (HUVEC) adhesiveness for neutrophils, E-selectin expression, neutrophil transmigration and IL-8 secretion were also reduced by up to 280-fold. On the other hand, D143F, a TNFR75-selective mutant tested either alone or in combination with TNFR55-selective mutants, did not stimulate these activities despite being able to cause cytokine production in TNFR75-transfected PC60 cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7509279      PMCID: PMC394883          DOI: 10.1002/j.1460-2075.1994.tb06327.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  46 in total

Review 1.  Clinical studies with TNF.

Authors:  T Taguchi; Y Sohmura
Journal:  Biotherapy       Date:  1991

2.  Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity.

Authors:  H Engelmann; H Holtmann; C Brakebusch; Y S Avni; I Sarov; Y Nophar; E Hadas; O Leitner; D Wallach
Journal:  J Biol Chem       Date:  1990-08-25       Impact factor: 5.157

3.  The two different receptors for tumor necrosis factor mediate distinct cellular responses.

Authors:  L A Tartaglia; R F Weber; I S Figari; C Reynolds; M A Palladino; D V Goeddel
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

4.  IL-8 in septic shock, endotoxemia, and after IL-1 administration.

Authors:  K J Van Zee; L E DeForge; E Fischer; M A Marano; J S Kenney; D G Remick; S F Lowry; L L Moldawer
Journal:  J Immunol       Date:  1991-05-15       Impact factor: 5.422

5.  Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor. Comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils.

Authors:  F Porteu; M Brockhaus; D Wallach; H Engelmann; C F Nathan
Journal:  J Biol Chem       Date:  1991-10-05       Impact factor: 5.157

6.  Effects on leukocytes after injection of tumor necrosis factor into healthy humans.

Authors:  T van der Poll; S J van Deventer; C E Hack; G J Wolbink; L A Aarden; H R Büller; J W ten Cate
Journal:  Blood       Date:  1992-02-01       Impact factor: 22.113

7.  Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences.

Authors:  Z Dembic; H Loetscher; U Gubler; Y C Pan; H W Lahm; R Gentz; M Brockhaus; W Lesslauer
Journal:  Cytokine       Date:  1990-07       Impact factor: 3.861

8.  Interleukin-8 induces neutrophil transendothelial migration.

Authors:  W B Smith; J R Gamble; I Clark-Lewis; M A Vadas
Journal:  Immunology       Date:  1991-01       Impact factor: 7.397

9.  Localization of the active site of human tumour necrosis factor (hTNF) by mutational analysis.

Authors:  X Van Ostade; J Tavernier; T Prangé; W Fiers
Journal:  EMBO J       Date:  1991-04       Impact factor: 11.598

10.  Binding and regulation of cellular functions by monoclonal antibodies against human tumor necrosis factor receptors.

Authors:  M R Shalaby; A Sundan; H Loetscher; M Brockhaus; W Lesslauer; T Espevik
Journal:  J Exp Med       Date:  1990-11-01       Impact factor: 14.307

View more
  31 in total

Review 1.  Tumor necrosis factor-α signaling in macrophages.

Authors:  Narayanan Parameswaran; Sonika Patial
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2010       Impact factor: 1.807

2.  Tumor necrosis factor-alpha from macrophages enhances LPS-induced clara cell expression of keratinocyte-derived chemokine.

Authors:  Arnon Elizur; Tracy L Adair-Kirk; Diane G Kelley; Gail L Griffin; Daphne E Demello; Robert M Senior
Journal:  Am J Respir Cell Mol Biol       Date:  2007-08-02       Impact factor: 6.914

3.  Tumor necrosis factor-alpha induces apoptosis of enterocytes in mice with fulminant hepatic failure.

Authors:  Hong-Li Song; Sa Lu; Pei Liu
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

4.  The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts.

Authors:  U Testa; F Grignani; P Samoggia; C Zanetti; R Riccioni; F Lo Coco; D Diverio; N Felli; C G Passerini; M Grell; P G Pelicci; C Peschle
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

5.  TNF-α type 2 receptor mediates renal inflammatory response to chronic angiotensin II administration with high salt intake in mice.

Authors:  Purnima Singh; Laleh Bahrami; Alexander Castillo; Dewan S A Majid
Journal:  Am J Physiol Renal Physiol       Date:  2013-02-06

6.  IL-1beta augments TNF-alpha-mediated inflammatory responses from lung epithelial cells.

Authors:  Sara Saperstein; Linlin Chen; David Oakes; Gloria Pryhuber; Jacob Finkelstein
Journal:  J Interferon Cytokine Res       Date:  2009-05       Impact factor: 2.607

7.  Release and activity of anti-TNFalpha therapeutics from injectable chitosan preparations for local drug delivery.

Authors:  Mohammed F Shamji; Priscilla Hwang; Robert W Bullock; Samuel B Adams; Dana L Nettles; Lori A Setton
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2009-07       Impact factor: 3.368

Review 8.  Regulation of serum amyloid A protein expression during the acute-phase response.

Authors:  L E Jensen; A S Whitehead
Journal:  Biochem J       Date:  1998-09-15       Impact factor: 3.857

9.  Molecular and functional evidence for in vitro cytokine enhancement of human and murine target cell sensitivity to glucocorticoids. TNF-alpha priming increases glucocorticoid inhibition of TNF-alpha-induced cytotoxicity/apoptosis.

Authors:  M Costas; T Trapp; M P Pereda; J Sauer; R Rupprecht; V E Nahmod; J M Reul; F Holsboer; E Arzt
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

10.  Treatment of neuroinflammation by soluble tumor necrosis factor receptor Type II fused to a thermally responsive carrier.

Authors:  Mohammed F Shamji; Liufang Jing; Jun Chen; Priscilla Hwang; Odelia Ghodsizadeh; Allan H Friedman; William J Richardson; Lori A Setton
Journal:  J Neurosurg Spine       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.